SLC34A3 Genotype

If you have had recurring kidney stones, unexplained low phosphate, or bone pain that started young, your standard labs might tell you something is off without telling you why. A variant in SLC34A3 (a gene that controls how your kidneys hold onto phosphate) can be the hidden driver behind all three, and it often runs quietly in families for years before anyone connects the dots.

This test looks at the actual DNA blueprint for a kidney transporter called NaPi-IIc. The result is a one-time genetic answer that explains a pattern of findings, points to specific follow-up tests, and shapes how aggressively you and your relatives should monitor your kidneys and bones over a lifetime.

What the Gene Actually Does

SLC34A3 carries the instructions for NaPi-IIc, a transporter protein that sits on the surface of cells lining the filtering tubes of your kidneys and reabsorbs phosphate from the urine back into the blood. Phosphate is the mineral your body uses, along with calcium, to build bone and to power almost every cell. When this transporter works normally, your kidneys quietly hang onto the right amount of phosphate all day.

When both copies of SLC34A3 carry damaging variants, the transporter cannot do its job. Phosphate leaks into urine, blood phosphate falls, and the body responds by making more active vitamin D, which then pulls extra calcium out of food. The extra calcium ends up in the urine, where it can form stones or deposit inside the kidneys. Bones, starved of phosphate, soften and bend in children and thin out in adults.

Hereditary Hypophosphatemic Rickets with Hypercalciuria

The classic disease tied to this gene is hereditary hypophosphatemic rickets with hypercalciuria, usually shortened to HHRH. It happens when both copies of SLC34A3 carry pathogenic variants. In a pooled analysis of 304 individuals, more than 90 percent of people with biallelic variants developed kidney or bone problems.

The picture is striking once you see it laid out together: low blood phosphate, high active vitamin D, high urine calcium, low or normal parathyroid hormone, and often rickets or osteomalacia, fractures, short stature, and kidney calcifications. In a case series of HHRH children, bone symptoms were the most common presentation, followed by kidney symptoms, then a combination of both. Some carriers were entirely asymptomatic at diagnosis.

Kidney Stones and Nephrocalcinosis

Kidney involvement is not just a feature of full-blown HHRH. In a UK 100,000 Genomes Project analysis of 374 stone formers and 24,930 controls, rare damaging variants in SLC34A3 turned out to be an important genetic risk factor for urinary stone disease, with about 5 percent of stone formers carrying qualifying variants versus 1.6 percent of controls. This helps explain part of the inherited risk that earlier common-variant studies had missed. People who carry only one damaged copy often present in adulthood with recurrent stones or nephrocalcinosis labeled as idiopathic.

A pediatric study of 113 children with kidney stones or kidney calcifications found that genetic testing returned an answer in about 32 percent of cases, with SLC34A3 especially common in the nephrocalcinosis group. If you or your child have had stones starting in childhood or young adulthood with high urine calcium, this gene belongs in the workup.

Bone Health Beyond Childhood

The bone story does not end after the growing years. Adults with SLC34A3 variants have been reported with stress fractures, low bone density, femoral fractures, and osteoporosis-like presentations that turn out to be driven by phosphate wasting rather than a typical aging skeleton. In one report, an adult was misdiagnosed with primary osteoporosis until a serum phosphate measurement pointed toward late-onset HHRH.

Even people with only one damaged copy can show bone density reduction or subtle bone changes alongside high urine calcium and elevated active vitamin D. If you have unexplained low bone density at a young age with low or low-normal phosphate, this is one of the genes worth checking.

Chronic Kidney Disease Risk

The most actionable adult finding comes from a cohort of 113 carriers of SLC34A3 or the related SLC34A1 gene. Adults with biallelic SLC34A3 variants had about six times the prevalence of chronic kidney disease compared with the general population. That risk is large enough that knowing your genotype changes how often you should be checking kidney function for the rest of your life, even when you feel well.

This is also where treatment nuance matters. Phosphate replacement, while standard care for low blood phosphate, can promote further kidney phosphate loss and push active vitamin D higher. In the 304-patient HHRH analysis, oral phosphate normalized serum phosphate but failed to resolve other outcomes in more than half of patients. That trade-off is one reason genotype-guided follow-up by a nephrologist or endocrinologist is more useful than generic supplementation.

Overlap with Other Genetic Conditions

SLC34A3 does not act alone. In families with overlapping vitamin D hypersensitivity, kidney stones, and hypophosphatemia, researchers have found combinations of variants across SLC34A3, the sister gene SLC34A1, and CYP24A1 (a gene controlling vitamin D breakdown). In a cohort of 185 patients screened for vitamin D hypersensitivity, no single mutation pattern dominated, which is why a panel approach often makes more sense than testing one gene at a time.

Digenic combinations, where you carry one damaging variant in SLC34A3 and another in SLC34A1, can produce dominant hypophosphatemic rickets with hypercalciuria that is more severe than either single variant alone. This is one reason a result here should be interpreted alongside companion genes when the clinical picture is suggestive.

A One-Time Test for a Lifetime Decision

Your SLC34A3 genotype does not change. A single accurate test gives you a permanent answer, and the genotype itself does not need to be repeated. The value comes from what you do with the result for the rest of your life. Carriers benefit from a tracking cadence built around phosphate, calcium, vitamin D, urine calcium, kidney function, and bone density rather than from retesting the gene.

A reasonable follow-up rhythm for someone with a biallelic result, extrapolated from natural history data rather than formal guidelines, includes blood phosphate, calcium, active vitamin D, parathyroid hormone, and a kidney function panel at baseline, then at least annually. Periodic 24-hour urine collections track calcium excretion, and kidney imaging plus bone density scans give a longitudinal view of stones, calcifications, and bone changes. People with one damaged copy benefit from a similar setup, scaled to symptoms and family history.

What an Unexpected Result Should Make You Do

If your test returns a pathogenic or likely pathogenic variant, the next move is not to retest the gene. It is to assemble the supporting picture: serum phosphate, calcium, ionized calcium, parathyroid hormone, 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D, magnesium, kidney function with creatinine and eGFR (a measure of how well your kidneys filter blood), plus a 24-hour urine for calcium and phosphate. Add a kidney ultrasound to look for stones or calcifications and a bone density scan if you have any bone symptoms.

A nephrologist or endocrinologist who works with hereditary phosphate disorders is the right specialist. Treatment in published series has centered on oral phosphate supplementation, which can correct blood phosphate, heal rickets, and reduce urine calcium, although active vitamin D often stays elevated and not every outcome reverses. Supportive measures such as generous fluid intake and a lower sodium diet have produced favorable kidney outcomes in pediatric series. Fluconazole, which lowers active vitamin D, reduced urine calcium in one SLC34A3 patient who had not responded to other treatment, though larger studies are needed and a randomized trial is underway.

What It Means for Your Family

Because SLC34A3 disease follows recessive inheritance for the full HHRH phenotype, your result has direct implications for biological parents, siblings, and children. Each first-degree relative has a meaningful chance of carrying at least one copy. Even one damaged copy can drive idiopathic hypercalciuria, recurrent stones, or subtle bone changes, so cascade testing through a genetic counselor is the most efficient way to find people who would benefit from monitoring.

When Results Can Be Misleading

• Variant panel coverage: this test detects only the variants the assay is designed to find. A negative result does not rule out rare or novel pathogenic variants in SLC34A3, including the intronic deletions that have been described in HHRH cohorts and missed by standard exon sequencing.
• Variants of uncertain significance: an unexpected variant may be reported with unclear clinical meaning. Functional studies, family segregation, and biochemical patterns help decide whether such a variant matters.
• Ancestry-specific frequencies: the clinical interpretation of a variant can depend on how common it is in your genetic background. Discuss your ancestry with the lab or a genetic counselor when interpreting borderline results.
• Direct-to-consumer reports: a 23andMe-style scan of SLC34A3 covers only a small number of variants and is not equivalent to a clinical-grade test. A negative consumer report does not mean you are in the clear if the clinical picture is suggestive.

Why a Single Genetic Test Is Different from Routine Labs

Normal blood phosphate, normal calcium, and normal kidney function on a standard panel do not rule out an SLC34A3 variant. The biochemical picture in heterozygous carriers can be intermittent, mild, or limited to a 24-hour urine collection that most adults never have done. The gene test answers a different question than a metabolic panel: it tells you what your kidneys are set up to do, not just what they are doing on the morning of one blood draw.